2009
Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo‐controlled trial
Abdelmalek M, Sanderson S, Angulo P, Soldevila‐Pico C, Liu C, Peter J, Keach J, Cave M, Chen T, McClain C, Lindor K. Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo‐controlled trial. Hepatology 2009, 50: 1818-1826. PMID: 19824078, DOI: 10.1002/hep.23239.Peer-Reviewed Original ResearchConceptsNonalcoholic steatohepatitisBetaine therapyHepatic steatosisAnimal studiesNonalcoholic fatty liver disease activity scoreBiopsy-proven nonalcoholic steatohepatitisRandomized placebo-controlled trialNonalcoholic fatty liver diseaseRandomized placebo-controlled studyPosttreatment liver biopsiesDisease Activity ScorePlacebo-controlled studyPlacebo-controlled trialFatty liver diseaseElevation of insulinNovel therapeutic optionsSecond hit mechanismsOral betaineWilcoxon rank testNASH patientsLiver biopsyActivity scoreLiver diseaseRemethylation of homocysteineSteatosis grade
2005
40 THE NATURAL HISTORY OF CRYPTOGENIC CIRRHOSIS FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATION: A HISTORICAL COHORT STUDY
Abdelmalek M, Mudaliar K, Liu C, Reed A, Nelson D, Asal N, Stacpoole P. 40 THE NATURAL HISTORY OF CRYPTOGENIC CIRRHOSIS FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATION: A HISTORICAL COHORT STUDY. Journal Of Investigative Medicine 2005, 53: s393. DOI: 10.2310/6650.2005.00205.39.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseLiver transplantationCryptogenic cirrhosisSteatosis gradeClinical dataMean age 53Repeat liver transplantationYr post-LTFatty liver diseaseInsulin resistance syndromeCardiovascular disease deathsPost-LTPre-LTMELD scoreGlycemic controlHDL cholesterolLiver biopsyInflammatory activityLDL cholesterolLiver diseaseDisease deathsResistance syndromeSingle pathologistClinicopathologic correlationRisk factors